Stay updated on Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.

Latest updates to the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, and API users can provide input before this change. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated to include more precise eligibility criteria for subjects in a clinical study involving Nivolumab, including specific laboratory values and age requirements. Additionally, the text has been revised to clarify the exclusion criteria for certain patient populations.SummaryDifference35%
- Check46 days agoChange DetectedThe webpage has undergone significant content removal, particularly regarding the detailed background and objectives of a study on Nivolumab for treating Epstein-Barr Virus-related lymphoproliferative disorders. The revision number has also been updated from v2.14.4 to v2.15.0.SummaryDifference55%
- Check53 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 17, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.2%
- Check60 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check75 days agoChange DetectedThe webpage has updated its contact information and important dates, replacing an old phone number and removing outdated dates.SummaryDifference0.4%
Stay in the know with updates to Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.